ArticleRisk management and healthcare policy2026
Cardiovascular Mortality in Amyloidosis: Long-Term Trends, Disparities, and Projections in the United States.
Article in Risk management and healthcare policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiac involvement is a major determinant of prognosis in systemic amyloidosis, but population-level trends in cardiovascular mortality remain insufficiently characterized. Methods: We performed a retrospective, population-based analysis of U.S. adults aged ≥45 years with amyloidosis using death certificate data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database from 1999 through 2023. Cardiovascular disease (CVD)-related deaths were identified using ICD-10 codes and classified into heart failure (HF), atrial fibrillation/flutter (AF), ischemic heart disease (IHD), or other CVD categories. Age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. standard population. Joinpoint regression assessed temporal trends, and autoregressive integrated moving average (ARIMA) models projected mortality through 2033. Results: A total of 35,222 CVD-related deaths occurred among adults with amyloidosis during the study period, yielding an overall AAMR of 1.12 per 100,000 population. Cardiovascular mortality increased nearly threefold, from 0.80 per 100,000 in 1999 to 2.27 per 100,000 in 2023, with a marked acceleration beginning in the late 2010s. HF consistently accounted for the largest proportion of CVD-related deaths. Mortality rates were higher among males, older adults, and non-Hispanic Black individuals, with demographic and geographic disparities widening over time. Similar upward trajectories were observed across U.S. Census regions and levels of urbanization. Projections indicated continued increases in cardiovascular mortality through 2033. Conclusion: Cardiovascular mortality among U.S. adults with amyloidosis has increased substantially over the past 25 years, with recent acceleration and persistent population-level disparities. These findings highlight a growing public health burden and support earlier detection, equitable access to specialized care, and continued national surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.